Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,188 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Prednisone Clear all
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 23, 2026, 11:08 AM EDT
Terminated Phase 2 Interventional Results available

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

NCT02420717
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Ph-Like Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin, Laboratory Biomarker Analysis, Leucovorin, Mercaptopurine, Methotrexate, Prednisone, Rituximab, Ruxolitinib Phosphate, Vincristine
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 23, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Results available

Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

NCT01327573
View directory record Official record
Conditions
Kidney; Complications, Allograft
Interventions
eculizumab
Drug
Lead sponsor
Sanjay Kulkarni
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Jul 23, 2026, 11:08 AM EDT
Recruiting Phase 2 Interventional

Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation

NCT05917522
View directory record Official record
Conditions
Kidney Transplant
Interventions
Abatacept, Standard of Care at US Transplant Centers
Biological · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 23, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Results available

An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

NCT00474383
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
Abiraterone acetate, Glucocorticoid
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Jul 23, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

NCT00002766
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
dactinomycin, sargramostim, carmustine, cyclophosphamide, cytarabine, daunorubicin hydrochloride, doxorubicin hydrochloride, etoposide, mercaptopurine, methotrexate, mitoxantrone hydrochloride, pegaspargase, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Stanford, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Jul 23, 2026, 11:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cemiplimab in AlloSCT/SOT Recipients With CSCC

NCT04339062
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
Interventions
Cemiplimab, Everolimus, Sirolimus, Prednisone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Jul 23, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Results available

Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00488982
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Docetaxel and GM-CSF
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jul 23, 2026, 11:08 AM EDT
Active, not recruiting Phase 2 Interventional

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

NCT03436654
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Abiraterone Acetate, Prednisone, GnRH agonist/antagonist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 23, 2026, 11:08 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Jul 23, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease

NCT00388362
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Sirolimus, Prednisone
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jul 23, 2026, 11:08 AM EDT
Withdrawn Phase 3 Interventional

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

NCT03532022
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort®, Standard Care
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Morehead City, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Jul 23, 2026, 11:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.

NCT00580229
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
prednisone
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Palm Harbor, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jul 23, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Results available

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

NCT02903160
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate, Prednisone, Radium-223 dichloride, cabazitaxel, Carboplatin, Enzalutamide
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Jul 23, 2026, 11:08 AM EDT
Terminated Phase 2 Interventional Results available

Abiraterone Acetate Trial in African American Prostate Cancer Patients

NCT01735396
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Jul 23, 2026, 11:08 AM EDT
Recruiting Phase 2 Interventional

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

NCT06563323
View directory record Official record
Conditions
Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
Interventions
Guselkumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Columbus, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 23, 2026, 11:08 AM EDT
Active, not recruiting Phase 2 Interventional

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

NCT03269669
View directory record Official record
Conditions
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Lenalidomide, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography, Prednisone, Umbralisib, Vincristine Sulfate
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
429
States / cities
Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 11:08 AM EDT
Completed No phase listed Observational

Study of Tolerant Kidney Transplant Recipients

NCT01338779
View directory record Official record
Conditions
Transplant Rejection, Kidney Transplantation, Renal Transplantation, Renal Transplant, Transplant Tolerance
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Bethesda, Maryland • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Jul 23, 2026, 11:08 AM EDT
Completed Phase 4 Interventional

Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection

NCT00885820
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus, MMF, Corticosteroids (Prednisone)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Jul 23, 2026, 11:08 AM EDT
Terminated Phase 2 Interventional Results available

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT02844582
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Stage IV Prostate Adenocarcinoma
Interventions
Cabazitaxel, Prednisone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Jul 23, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers

NCT02767089
View directory record Official record
Conditions
Healthy Adults
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Jul 23, 2026, 11:08 AM EDT
Withdrawn Phase 2 Interventional

Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)

NCT02702960
View directory record Official record
Conditions
Fibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma (Fibrolamellar Variant), Hepatocellular Carcinoma
Interventions
living related donor partial liver transplantation, Total body irradiation, Bone marrow transplant from same donor, Cyclophosphamide, Mesna, Filgrastim, Tacrolimus, mycophenolate mofetil, Prednisone, Antithymocyte globulin, fludarabine
Procedure · Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
16 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Jul 23, 2026, 11:08 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

NCT02159690
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Cancer
Interventions
Enzalutamide, Abiraterone acetate, Prednisone, Dutasteride, Degarelix
Drug
Lead sponsor
Kenneth Pienta, MD
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Jul 23, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

NCT00417079
View directory record Official record
Conditions
Neoplasms, Prostatic Neoplasms
Interventions
cabazitaxel (XRP6258) (RPR116258), mitoxantrone, prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Jul 23, 2026, 11:08 AM EDT